Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nidan Laboratories and Healthcare has a current ratio of 1.10. It generally indicates good short-term financial strength.
The historical rank and industry rank for Nidan Laboratories and Healthcare's Current Ratio or its related term are showing as below:
NSE:NIDAN's Current Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.1 * Ranked among companies with meaningful Current Ratio only.
Nidan Laboratories and Healthcare (NSE:NIDAN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Nidan Laboratories and Healthcare Current Ratio Related Terms
Nidan Laboratories and Healthcare Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare Current Ratio Chart
NSE:NIDAN vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Nidan Laboratories and Healthcare's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nidan Laboratories and Healthcare Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Nidan Laboratories and Healthcare's Current Ratio distribution charts can be found below:
* The bar in red indicates where Nidan Laboratories and Healthcare's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare (NSE:NIDAN) has a Current Ratio of 1.10 as of Mar. 2025.
Is Nidan Laboratories and Healthcare's Current Ratio too high?
Nidan Laboratories and Healthcare's current Current Ratio is 1.10. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Nidan Laboratories and Healthcare's value of 1.10 is 47.6% below this industry median. Overall, Nidan Laboratories and Healthcare has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Nidan Laboratories and Healthcare's Current Ratio compare to TMO and DHR?
Nidan Laboratories and Healthcare's Current Ratio of 1.10 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Current Ratio is 2.10. Nidan Laboratories and Healthcare's value of 1.10 is 47.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nidan Laboratories and Healthcare's current Current Ratio of 1.10 is 47.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nidan Laboratories and Healthcare's current Current Ratio is 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nidan Laboratories and Healthcare stock overvalued right now?
Nidan Laboratories and Healthcare (NSE:NIDAN) has a current Current Ratio of 1.10. The current Current Ratio is 1.10 and 47.6% below the Medical Diagnostics & Research industry median of 2.10. Nidan Laboratories and Healthcare's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Nidan Laboratories and Healthcare (NSE:NIDAN), the current Current Ratio is 1.10 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nidan Laboratories and Healthcare Business Description
Nidan Laboratories and Healthcare Ltd offer diagnostic services including radiology, neurology, cardiology, dental as well as pathology services. The company provides pathology tests ranging from basic biochemistry and clinical pathology to cytogenetic and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-Rays, and ultrasounds to radiology tests including computerized tomography scans, magnetic resonance imaging scans.
67GF Score
Get the complete analysis for NSE:NIDAN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NIDAN has been successfully added to your 
